Cerebrolysin

Estimated Market Price

$134.99 – $149.99

Based on verified supplier pricing for research-grade compounds

Neuropeptide complex with neurotrophic properties. Approved in 40+ countries for cognitive conditions. Promotes neurogenesis, synaptogenesis, and neuroprotection.

How it works

A mix of small neurotrophic peptides that mimic your brain's own growth factors (BDNF, NGF) to protect neurons, build new synaptic connections, and promote neuroplasticity. Small enough to cross the blood-brain barrier.

Focus & Cognition

What to Expect

Days 1–3 Neurotrophic factors crossing BBB; initial neuroprotection. Subtle mental clarity; thoughts feel a bit crisper.

Days 4–10 Synaptogenesis activated; cognitive clarity improving. Focus improving; conversations and reading feel easier.

Days 11–15 Neuroplasticity peak; memory and learning enhanced. Memory sharper; learning new information comes faster.

Days 16–20 Cycle completing; benefits consolidating post-treatment. Peak cognitive boost; mental performance at its best.

Month 2–3 Off-cycle; repeat as needed based on clinical assessment. Benefits persist after cycle; brain feels refreshed.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier

LarnaLabs Verified Supplier · larnalabs.com

NXPeptides Verified Supplier · nxpeptides.com

BioSynth Verified Custom Batch Supplier · biosynth.com

Peptide Sciences Unavailable · peptidesciences.com

Protocol & Dosage

Typical Dosage 5–30 mL IV or IM daily

Administration Intravenous, Intramuscular

Schedule Once daily IV/IM for 10–20 day cycles

Protocol Duration 10–20 day cycles

Half-Life Variable (mixture)

Side Effects & Safety

Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

Headache~5%
Dizziness~3%
Injection site reactionsome users

Less Common

Agitation or restlessnessoccasional
Nauseaoccasional
Flu-like symptomsoccasional
Insomniaoccasional
Excessive sweatingoccasional

Rare / Serious

Allergic reactionrare
Confusion in elderly patientsrare

Discontinue If

Severe allergic reaction (porcine-derived product)
Persistent confusion or agitation
Seizures

Contraindications

Known porcine protein allergy
Active bleeding disorders
Pregnancy or breastfeeding
Severe renal impairment
Status epilepticus

Data note: Approved in 40+ countries for stroke and dementia. Extensive post-marketing surveillance data. Not available in the US.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about Cerebrolysin

How to Apply

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

Sanitize

Wipe tops of both vials with alcohol swabs

Draw

Pull 1–2 mL of BAC water into syringe

Add Water

Release water slowly along vial wall, not directly on powder

Swirl

Roll between palms until dissolved. Never shake.

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for Cerebrolysin

Also Known As Cerebrolysin®, FPF-1070

Classification Neuropeptide Mixture · Neurotrophic

Sequence Mixture of low-molecular-weight neuropeptides and amino acids from porcine brain

Molecular Formula Complex mixture

Molecular Weight <10,000 Da (peptide fraction)

CAS Number 12656-61-0

Half-Life Variable (mixture)

Origin Enzymatic digest of purified porcine brain proteins

Administration Intravenous, Intramuscular

Status Approved in 50+ countries - stroke, TBI, dementia (not FDA approved)

Mechanism of Action A mix of small neurotrophic peptides that mimic your brain's own growth factors (BDNF, NGF) to protect neurons, build new synaptic connections, and promote neuroplasticity. Small enough to cross the blood-brain barrier.

Research Overview Cerebrolysin is a complex pharmaceutical preparation consisting of low-molecular-weight neuropeptides and free amino acids derived from the enzymatic proteolysis of purified porcine brain tissue, produced by EVER Neuro Pharma in Austria. The manufacturing process involves controlled pepsin degradation of porcine brain proteins, followed by ultrafiltration to select peptide fragments below 10 kDa, resulting in a standardized mixture where approximately 25% of the dry weight consists of peptides and 75% consists of free amino acids. First introduced into clinical practice in Europe in 1975, Cerebrolysin has been approved for medical use in over 50 countries worldwide - primarily in Europe, Asia, and Latin America - for a range of neurological conditions including stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease, though it has never received FDA approval and remains unavailable in the United States and United Kingdom. The neurotrophic hypothesis underlying Cerebrolysin's mechanism proposes that the peptide mixture contains fragments that functionally mimic endogenous neurotrophic factors including BDNF, GDNF, NGF, and CNTF. In vitro and in vivo studies have demonstrated that Cerebrolysin promotes neuronal survival, stimulates neurite outgrowth, enhances synaptogenesis, reduces amyloid-beta peptide aggregation, inhibits tau hyperphosphorylation, and modulates brain neuroplasticity. A large body of clinical trial evidence exists, though the quality and methodology have been variable. The CASTA trial (Cerebrolysin and Recovery After Stroke) involving 1,070 patients showed improvements in global function and neurological scores at 90 days post-stroke, though not all endpoints reached statistical significance. In Alzheimer's disease, randomized controlled trials demonstrated improvements in cognitive function scores (ADAS-cog) and global clinical impression with Cerebrolysin treatment over 24 weeks. The compound's ability to cross the blood-brain barrier - enabled by the small size of its constituent peptides - is considered a key advantage over recombinant neurotrophic factor proteins which generally cannot penetrate the BBB.

Citations

Published findings on Cerebrolysin from peer-reviewed journals.

Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

Guekht AB, et al. • 2011 PubMed

The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders

Hartbauer M, et al. • 2001 PubMed

Cerebrolysin: a multi-target drug for recovery after stroke

Bornstein NM, et al. • 2018 PubMed